Production (Stage)
VYNE Therapeutics Inc.
VYNE
$1.04
$0.044.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 28.37% | 1.11% | -29.25% | -50.52% | -0.99% |
| Total Depreciation and Amortization | 50.00% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 185.06% | -32.75% | -14.87% | 29.95% | -54.61% |
| Change in Net Operating Assets | -215.01% | -16.18% | 421.04% | 133.83% | -425.88% |
| Cash from Operations | -27.36% | -5.75% | -0.34% | -6.26% | -55.36% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 54.27% | 366.48% | -125.36% | 632.92% | 94.28% |
| Cash from Investing | 55.68% | 364.05% | -125.36% | 632.92% | 94.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 34.09% | -6,500.00% | 33.33% | 40.00% | -150.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 34.09% | -6,500.00% | 33.33% | 40.00% | -100.01% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 129.64% | 127.05% | -226.58% | 191.18% | -176.16% |